Recent Updates
Recently added Catalysts
VERA

Vera Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

Key Takeaway: SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+38%
120-day peak, hindsight
Typical move
3.5%
average across 4 past catalysts
Cash runway
~15 mo
Low dilution risk
Lead asset
Atacicept
Phase 3 · IgA Nephropathy

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that management will provide a corporate presentation and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference, which is taking place June 1-4, 2021.
Presentation details:
Date: Friday, June 4, 2021
Time: 9:00 AM PT (12:00 PM ET)
Presenter: Marshall Fordyce, MD, CEO and Founder of Vera
A live webcast of the presentation can be accessed by visiting the investor relations section of the Company’s website, www.veratx.com. A replay of the webcast will also be available and archived on the site for 90 days following the presentation date.
About Vera Therapeutics
Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera’s lead program is atacicept, a fusion protein that is in development for IgA nephropathy, a disease with high unmet medical need and no approved therapies. In addition, Vera is evaluating additional diseases where atacicept’s reduction of autoantibodies may prove medically useful, including lupus nephritis (LN), a severe renal manifestation of systemic lupus erythematosus (SLE). For more information please visit www.veratx.com.
Greig Communications, Inc.
Last updated: May 27, 2021